GENE ONLINE|News &
Opinion
Blog

2022-12-14| In-DepthSpecial

A Force To Be Reckoned With – BioBetter Biologics

by GeneOnline
Share To
Off-patent biologics are a large market for ‘follow-on’ biologics. Biobetters, in particular, are novel innovations designed to be therapeutically more efficient and safer. They present a new market territory and have witnessed growing interest among drug manufacturers in recent years.

The marketing term ‘biobetter’ was coined in a Mumbai bio-conference in 2007 by Mr. GV Prasa, an Indian business executive, and has been markedly used ever since. Biobetters are novel highly-differentiated entities with strong bio-superiority over existing approved biologics. They are the result of cutting-edge research and novel chemical/molecular modifications (e.g. PEGylation/residue substitutions), and boast enhanced therapeutic benefits, such as improved potency and selectivity, increased bioavailability, longer half-life, and better safety.

GO Prime with only $1.49 now

LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top